<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36765396</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1479-5876</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>10</Day></PubDate></JournalIssue><Title>Journal of translational medicine</Title><ISOAbbreviation>J Transl Med</ISOAbbreviation></Journal><ArticleTitle>Bioinformatics analyses of combined databases identify shared differentially expressed genes in cancer and autoimmune disease.</ArticleTitle><Pagination><StartPage>109</StartPage><MedlinePgn>109</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">109</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12967-023-03943-9</ELocationID><Abstract><AbstractText Label="BACKGROUND">Inadequate immunity caused by poor immune surveillance leads to tumorigenesis, while excessive immunity due to breakdown of immune tolerance causes autoimmune genesis. Although the function of immunity during the onset of these two processes appears to be distinct, the underlying mechanism is shared. To date, gene expression data for large bodies of clinical samples are available, but the resemblances of tumorigenesis and autoimmune genesis in terms of immune responses remains to be summed up.</AbstractText><AbstractText Label="METHODS">Considering the high disease prevalence, we chose invasive ductal carcinoma (IDC) and systemic lupus erythematosus (SLE) to study the potential commonalities of immune responses. We obtained gene expression data of IDC/SLE patients and normal controls from five IDC databases (GSE29044, GSE21422, GSE22840, GSE15852, and GSE9309) and five SLE databases (GSE154851, GSE99967, GSE61635, GSE50635, and GSE17755). We intended to identify genes differentially expressed in both IDC and SLE by using three bioinformatics tools including GEO2R, the limma R package, and Weighted Gene Co-expression Network Analysis (WGCNA) to perform function enrichment, protein-protein network, and signaling pathway analyses.</AbstractText><AbstractText Label="RESULTS">The mRNA levels of signal transducer and activator of transcription 1 (STAT1), 2'-5'-oligoadenylate synthetase 1 (OAS1), 2'-5'-oligoadenylate synthetase like (OASL), and PML nuclear body scaffold (PML) were found to be differentially expressed in both IDC and SLE by using three different bioinformatics tools of GEO2R, the limma R package and WGCNA. From the combined databases in this study, the mRNA levels of STAT1 and OAS1 were increased in IDC while reduced in SLE. And the mRNA levels of OASL and PML were elevated in both IDC and SLE. Based on Kyoto Encyclopedia of Genes and Genomes pathway analysis and QIAGEN Ingenuity Pathway Analysis, both IDC and SLE were correlated with the changes of multiple components involved in the Interferon (IFN)-Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway.</AbstractText><AbstractText Label="CONCLUSION">The expression levels of STAT1 and OAS1 manifest the opposite expression tendency across cancer and autoimmune disease. They are components in the&#xa0;IFN-JAK-STAT signaling pathway related to both tumorigenesis and autoimmune genesis. STAT1 and OAS1-associated IFN-JAK-STAT signaling could explain the commonalities during tumorigenesis and autoimmune genesis and render significant information for more precise treatment from the point of immune homeostasis.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sui</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Edmond H. Fischer Signal Transduction Laboratory, School of Life Sciences, Jilin University, Changchun, 130012, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shuping</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Xue-Qi</ForeName><Initials>XQ</Initials><AffiliationInfo><Affiliation>Edmond H. Fischer Signal Transduction Laboratory, School of Life Sciences, Jilin University, Changchun, 130012, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Zhizhuang Joe</ForeName><Initials>ZJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA. joe-zhao@ouhsc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xing</LastName><ForeName>Shu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Edmond H. Fischer Signal Transduction Laboratory, School of Life Sciences, Jilin University, Changchun, 130012, China. xingshu@jlu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Transl Med</MedlineTA><NlmUniqueID>101190741</NlmUniqueID><ISSNLinking>1479-5876</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.10.2</RegistryNumber><NameOfSubstance UI="D053612">Janus Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053612" MajorTopicYN="N">Janus Kinases</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063646" MajorTopicYN="N">Carcinogenesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoimmune genesis</Keyword><Keyword MajorTopicYN="N">IFN-JAK-STAT signaling pathway</Keyword><Keyword MajorTopicYN="N">Invasive ductal carcinoma</Keyword><Keyword MajorTopicYN="N">OAS1</Keyword><Keyword MajorTopicYN="N">OASL</Keyword><Keyword MajorTopicYN="N">PML</Keyword><Keyword MajorTopicYN="N">STAT1</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">Tumorigenesis</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>11</Day><Hour>0</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36765396</ArticleId><ArticleId IdType="pmc">PMC9921081</ArticleId><ArticleId IdType="doi">10.1186/s12967-023-03943-9</ArticleId><ArticleId IdType="pii">10.1186/s12967-023-03943-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tordesillas L, Berin MC, Sampson HA. Immunology of food allergy. Immunity. 2017;47(1):32&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">28723552</ArticleId></ArticleIdList></Reference><Reference><Citation>Lockhart A, Mucida D, Parsa R. Immunity to enteric viruses. Immunity. 2022;55(5):800&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9257994</ArticleId><ArticleId IdType="pubmed">35545029</ArticleId></ArticleIdList></Reference><Reference><Citation>Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6831096</ArticleId><ArticleId IdType="pubmed">31315034</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Vignali DA. Co-stimulatory and Co-inhibitory pathways in autoimmunity. Immunity. 2016;44(5):1034&#x2013;1051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4873959</ArticleId><ArticleId IdType="pubmed">27192568</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Strasser A, Kelly GL. Should mutant TP53 be targeted for cancer therapy? Cell Death Differ. 2022;29(5):911&#x2013;920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9091235</ArticleId><ArticleId IdType="pubmed">35332311</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;ttcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell. 2018;172(5):1022&#x2013;37.e14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5847168</ArticleId><ArticleId IdType="pubmed">29429633</ArticleId></ArticleIdList></Reference><Reference><Citation>Finisguerra V, Di Conza G, Di Matteo M, Serneels J, Costa S, Thompson AA, et al. MET is required for the recruitment of anti-tumoural neutrophils. Nature. 2015;522(7556):349&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4594765</ArticleId><ArticleId IdType="pubmed">25985180</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32(19&#x2013;20):1267&#x2013;1284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6169832</ArticleId><ArticleId IdType="pubmed">30275043</ArticleId></ArticleIdList></Reference><Reference><Citation>Showalter A, Limaye A, Oyer JL, Igarashi R, Kittipatarin C, Copik AJ, et al. Cytokines in immunogenic cell death: applications for cancer immunotherapy. Cytokine. 2017;97:123&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5572581</ArticleId><ArticleId IdType="pubmed">28648866</ArticleId></ArticleIdList></Reference><Reference><Citation>Moretta A, Marcenaro E, Sivori S, Della Chiesa M, Vitale M, Moretta L. Early liaisons between cells of the innate immune system in inflamed peripheral tissues. Trends Immunol. 2005;26(12):668&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pubmed">16198147</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz RH. Acquisition of immunologic self-tolerance. Cell. 1989;57(7):1073&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pubmed">2525422</ArticleId></ArticleIdList></Reference><Reference><Citation>Durcan L, O'Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019;393(10188):2332&#x2013;2343.</Citation><ArticleIdList><ArticleId IdType="pubmed">31180030</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto M, Delatorre N, Hurst C, Rodgers KE. Targeting the protective arm of the renin-angiotensin system to reduce systemic lupus erythematosus related pathologies in MRL-lpr mice. Front Immunol. 2020;11:1572.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7390909</ArticleId><ArticleId IdType="pubmed">32793221</ArticleId></ArticleIdList></Reference><Reference><Citation>Krovi SH, Kuchroo VK. Activation pathways that drive CD4(+) T cells to break tolerance in autoimmune diseases() Immunol Rev. 2022;307(1):161&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9255211</ArticleId><ArticleId IdType="pubmed">35142369</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann C, Noel F, Grandclaudon M, Massenet-Regad L, Michea P, Sirven P, et al. PD-L1 and ICOSL discriminate human Secretory and Helper dendritic cells in cancer, allergy and autoimmunity. Nat Commun. 2022;13(1):1983.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9008048</ArticleId><ArticleId IdType="pubmed">35418195</ArticleId></ArticleIdList></Reference><Reference><Citation>Policheni AN, Teh CE, Robbins A, Tuzlak S, Strasser A, Gray DHD. PD-1 cooperates with AIRE-mediated tolerance to prevent lethal autoimmune disease. Proc Natl Acad Sci USA. 2022;119(15):e2120149119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9169857</ArticleId><ArticleId IdType="pubmed">35394861</ArticleId></ArticleIdList></Reference><Reference><Citation>Markmann C, Bhoj VG. On the road to eliminating long-lived plasma cells-"are we there yet?". Immunol Rev. 2021;303(1):154&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">34351644</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulthei&#xdf; C, Steinmann S, Lohse AW, Binder M. B cells in autoimmune hepatitis: bystanders or central players? Seminars in immunopathology. 2022;44(4):411&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9256567</ArticleId><ArticleId IdType="pubmed">35488094</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger MF, Van Allen EM. Delivering on the promise of precision cancer medicine. Genome Med. 2016;8(1):110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5078954</ArticleId><ArticleId IdType="pubmed">27782852</ArticleId></ArticleIdList></Reference><Reference><Citation>Schupack DA, Mars RAT, Voelker DH, Abeykoon JP, Kashyap PC. The promise of the gut microbiome as part of individualized treatment strategies. Nat Rev Gastroenterol Hepatol. 2022;19(1):7&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8712374</ArticleId><ArticleId IdType="pubmed">34453142</ArticleId></ArticleIdList></Reference><Reference><Citation>Guthridge JM, Wagner CA, James JA. The promise of precision medicine in rheumatology. Nat Med. 2022;28(7):1363&#x2013;1371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9513842</ArticleId><ArticleId IdType="pubmed">35788174</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA: a Cancer J Clin. 2022;72(1):7&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">35020204</ArticleId></ArticleIdList></Reference><Reference><Citation>Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast cancer statistics, 2022. CA: a Cancer J Clin. 2022;72(6):524&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">36190501</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: a J Clin. 2018;68(1):7&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">29313949</ArticleId></ArticleIdList></Reference><Reference><Citation>Mojra A, Hooman K. Viscoelastic parameters of invasive breast cancer in correlation with porous structure and elemental analysis data. Comput Methods Programs Biomed. 2021;212:106482.</Citation><ArticleIdList><ArticleId IdType="pubmed">34736165</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsokos GC. Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol. 2020;21(6):605&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8135909</ArticleId><ArticleId IdType="pubmed">32367037</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110&#x2013;2121.</Citation><ArticleIdList><ArticleId IdType="pubmed">22129255</ArticleId></ArticleIdList></Reference><Reference><Citation>Colak D, Nofal A, Albakheet A, Nirmal M, Jeprel H, Eldali A, et al. Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women. PLoS ONE. 2013;8(5):e63204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3660335</ArticleId><ArticleId IdType="pubmed">23704896</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics (Oxford, England) 2012;28(6):882&#x2013;883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3307112</ArticleId><ArticleId IdType="pubmed">22257669</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631488</ArticleId><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis G, Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003;4(5):P3.</Citation><ArticleIdList><ArticleId IdType="pubmed">12734009</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498&#x2013;2504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98&#x2013;w102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5570223</ArticleId><ArticleId IdType="pubmed">28407145</ArticleId></ArticleIdList></Reference><Reference><Citation>Martorell-Marug&#xe1;n J, L&#xf3;pez-Dom&#xed;nguez R, Garc&#xed;a-Moreno A, Toro-Dom&#xed;nguez D, Villatoro-Garc&#xed;a JA, Barturen G, et al. A comprehensive database for integrated analysis of omics data in autoimmune diseases. BMC Bioinformatics. 2021;22(1):343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8223391</ArticleId><ArticleId IdType="pubmed">34167460</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W, Zhou H, Hodgkinson C, Montero A, Goldman D, Chang SL. Network meta-analysis on the mechanisms underlying alcohol augmentation of COVID-19 pathologies. Alcohol Clin Exp Res. 2021;45(4):675&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014161</ArticleId><ArticleId IdType="pubmed">33583045</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Boutros PC. VennDiagram: a package for the generation of highly-customizable Venn and Euler diagrams in R. BMC Bioinformatics. 2011;12:35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041657</ArticleId><ArticleId IdType="pubmed">21269502</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu D, Di S, Zhuo S, Zhou L, Bai R, Ma T, et al. The long noncoding RNA TINCR promotes breast cancer cell proliferation and migration by regulating OAS1. Cell Death Discov. 2021;7(1):41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7921111</ArticleId><ArticleId IdType="pubmed">33649294</ArticleId></ArticleIdList></Reference><Reference><Citation>Erdogan F, Radu TB, Orlova A, Qadree AK, de Araujo ED, Israelian J, et al. JAK-STAT core cancer pathway: an integrative cancer interactome analysis. J Cell Mol Med. 2022;26(7):2049&#x2013;2062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8980946</ArticleId><ArticleId IdType="pubmed">35229974</ArticleId></ArticleIdList></Reference><Reference><Citation>Novakova Z, Hubackova S, Kosar M, Janderova-Rossmeislova L, Dobrovolna J, Vasicova P, et al. Cytokine expression and signaling in drug-induced cellular senescence. Oncogene. 2010;29(2):273&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">19802007</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee WB, Choi WY, Lee DH, Shim H, Kim-Ha J, Kim YJ. OAS1 and OAS3 negatively regulate the expression of chemokines and interferon-responsive genes in human macrophages. BMB Rep. 2019;52(2):133&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6443328</ArticleId><ArticleId IdType="pubmed">30078389</ArticleId></ArticleIdList></Reference><Reference><Citation>Braunstein I, Klein R, Okawa J, Werth VP. The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score. Br J Dermatol. 2012;166(5):971&#x2013;975.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3336025</ArticleId><ArticleId IdType="pubmed">22242767</ArticleId></ArticleIdList></Reference><Reference><Citation>Arreal L, Piva M, Fern&#xe1;ndez S, Revandkar A, Schaub-Clerigu&#xe9; A, Villanueva J, et al. Targeting PML in triple negative breast cancer elicits growth suppression and senescence. Cell Death Differ. 2020;27(4):1186&#x2013;1199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7104349</ArticleId><ArticleId IdType="pubmed">31570853</ArticleId></ArticleIdList></Reference><Reference><Citation>Tampakaki M, Oraiopoulou M-E, Tzamali E, Tzedakis G, Makatounakis T, Zacharakis G, et al. PML differentially regulates growth and invasion in brain cancer. Int J Mol Sci. 2021;22(12):6289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8230868</ArticleId><ArticleId IdType="pubmed">34208139</ArticleId></ArticleIdList></Reference><Reference><Citation>Nataraja C, Flynn J, Dankers W, Northcott M, Zhu W, Sherlock R, et al. GILZ regulates type I interferon release and sequesters STAT1. J Autoimmun. 2022;131:102858.</Citation><ArticleIdList><ArticleId IdType="pubmed">35810690</ArticleId></ArticleIdList></Reference><Reference><Citation>Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of the mouse stat1 gene results in compromised innate immunity to viral disease. Cell. 1996;84(3):443&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">8608598</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang E, Li MMH. All about the RNA: interferon-stimulated genes that interfere with viral RNA processes. Front Immunol. 2020;11:605024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7756014</ArticleId><ArticleId IdType="pubmed">33362792</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Higgs RE, Hoffman RW, Dow ER, Liu X, Petri M, et al. A Bayesian gene network reveals insight into the JAK-STAT pathway in systemic lupus erythematosus. PLoS ONE. 2019;14(12):e0225651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6886858</ArticleId><ArticleId IdType="pubmed">31790472</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen M, Duan C, Xie C, Wang H, Li Z, Li B, et al. Identification of key interferon-stimulated genes for indicating the condition of patients with systemic lupus erythematosus. Front Immunol. 2022;13:962393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9365928</ArticleId><ArticleId IdType="pubmed">35967341</ArticleId></ArticleIdList></Reference><Reference><Citation>Raftery N, Stevenson NJ. Advances in anti-viral immune defence: revealing the importance of the IFN JAK/STAT pathway. Cell Mol Life Sci: CMLS. 2017;74(14):2525&#x2013;2535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7079803</ArticleId><ArticleId IdType="pubmed">28432378</ArticleId></ArticleIdList></Reference><Reference><Citation>Isaacs A, Lindenmann J. Virus interference. I .The interferon. Proc R Soc Lond Series B, Biol Sci. 1957;147(927):258&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">13465720</ArticleId></ArticleIdList></Reference><Reference><Citation>Aaronson DS, Horvath CM. A road map for those who don't know JAK-STAT. Science (New York, NY) 2002;296(5573):1653&#x2013;1655.</Citation><ArticleIdList><ArticleId IdType="pubmed">12040185</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks AJ, Dai W, O'Mara ML, Abankwa D, Chhabra Y, Pelekanos RA, et al. Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science (New York, NY) 2014;344(6185):1249783.</Citation><ArticleIdList><ArticleId IdType="pubmed">24833397</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014;32:513&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4313732</ArticleId><ArticleId IdType="pubmed">24555472</ArticleId></ArticleIdList></Reference><Reference><Citation>Padariya M, Sznarkowska A, Kote S, G&#xf3;mez-Herranz M, Mikac S, Pilch M, et al. Functional interfaces, biological pathways, and regulations of interferon-related DNA damage resistance signature (IRDS) genes. Biomolecules. 2021;11(5):622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8143464</ArticleId><ArticleId IdType="pubmed">33922087</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang D, Wu Q, Yuan Z, Xu J, Zhang H, Jin Z, et al. Identification of key pathways and genes changes in pancreatic cancer cells (BXPC-3) after cross-talk with primary pancreatic stellate cells using bioinformatics analysis. Neoplasma. 2019;66(5):681&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pubmed">31169017</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai MH, Cook JA, Chandramouli GV, DeGraff W, Yan H, Zhao S, et al. Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. Cancer Res. 2007;67(8):3845&#x2013;3852.</Citation><ArticleIdList><ArticleId IdType="pubmed">17440099</ArticleId></ArticleIdList></Reference><Reference><Citation>Seoane J, Gomis RR. TGF-&#x3b2; family signaling in tumor suppression and cancer progression. Cold Spring Harb perspect Biol. 2017;9(12):a022277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5710110</ArticleId><ArticleId IdType="pubmed">28246180</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang PC, Chung JY, Xue VW, Xiao J, Meng XM, Huang XR, et al. Smad3 promotes cancer-associated fibroblasts generation via macrophage-myofibroblast transition. Adv Sci (Weinheim, Baden-Wurttemberg, Germany) 2022;9(1):e2101235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8728853</ArticleId><ArticleId IdType="pubmed">34791825</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue VW, Chung JY, C&#xf3;rdoba CAG, Cheung AH, Kang W, Lam EW, et al. Transforming growth factor-&#x3b2;: a multifunctional regulator of cancer immunity. Cancers. 2020;12(11):3099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7690808</ArticleId><ArticleId IdType="pubmed">33114183</ArticleId></ArticleIdList></Reference><Reference><Citation>Santhana Kumar K, Neve A, Guerreiro Stucklin AS, Kuzan-Fischer CM, Rushing EJ, Taylor MD, et al. TGF-&#x3b2; determines the pro-migratory potential of bFGF signaling in medulloblastoma. Cell Rep. 2018;23(13):3798&#x2013;812.e8.</Citation><ArticleIdList><ArticleId IdType="pubmed">29949765</ArticleId></ArticleIdList></Reference><Reference><Citation>Thien A, Prentzell MT, Holzwarth B, Kl&#xe4;sener K, Kuper I, Boehlke C, et al. TSC1 activates TGF-&#x3b2;-Smad2/3 signaling in growth arrest and epithelial-to-mesenchymal transition. Dev Cell. 2015;32(5):617&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">25727005</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho JH, Oh AY, Park S, Kang SM, Yoon MH, Woo TG, et al. Loss of NF2 induces TGF&#x3b2; Receptor 1-mediated noncanonical and oncogenic TGF&#x3b2; signaling: Implication of the therapeutic effect of TGF&#x3b2; receptor 1 inhibitor on NF2 syndrome. Mol Cancer Ther. 2018;17(11):2271&#x2013;2284.</Citation><ArticleIdList><ArticleId IdType="pubmed">30135214</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobin SW, Douville K, Benbow U, Brinckerhoff CE, Memoli VA, Arrick BA. Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects. Oncogene. 2002;21(1):108&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">11791181</ArticleId></ArticleIdList></Reference><Reference><Citation>Li&#xe9;nart S, Merceron R, Vanderaa C, Lambert F, Colau D, Stockis J, et al. Structural basis of latent TGF-&#x3b2;1 presentation and activation by GARP on human regulatory T cells. Science (New York, NY) 2018;362(6417):952&#x2013;956.</Citation><ArticleIdList><ArticleId IdType="pubmed">30361387</ArticleId></ArticleIdList></Reference><Reference><Citation>Freudlsperger C, Bian Y, Contag Wise S, Burnett J, Coupar J, Yang X, et al. TGF-&#x3b2; and NF-&#x3ba;B signal pathway cross-talk is mediated through TAK1 and SMAD7 in a subset of head and neck cancers. Oncogene. 2013;32(12):1549&#x2013;1559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3434281</ArticleId><ArticleId IdType="pubmed">22641218</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan MK, Chung JY, Tang PC, Chan AS, Ho JY, Lin TP, et al. TGF-&#x3b2; signaling networks in the tumor microenvironment. Cancer Lett. 2022;550:215925.</Citation><ArticleIdList><ArticleId IdType="pubmed">36183857</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang QM, Tang PM, Lian GY, Li C, Li J, Huang XR, et al. Enhanced cancer immunotherapy with Smad3-silenced NK-92 cells. Cancer Immunol Res. 2018;6(8):965&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pubmed">29915022</ArticleId></ArticleIdList></Reference><Reference><Citation>Lian GY, Wang QM, Tang PM, Zhou S, Huang XR, Lan HY. Combination of asiatic acid and naringenin modulates NK cell anti-cancer immunity by rebalancing Smad3/Smad7 signaling. Mol Ther: the journal of the American Society of Gene Therapy. 2018;26(9):2255&#x2013;2266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6127879</ArticleId><ArticleId IdType="pubmed">30017880</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, He J, He L, Xu B, Wang Q. Expression and function of Smad7 in autoimmune and inflammatory diseases. J Mol Med (Berl) 2021;99(9):1209&#x2013;1220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8367892</ArticleId><ArticleId IdType="pubmed">34059951</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou G, Sun X, Qin Q, Lv J, Cai Y, Wang M, et al. Loss of Smad7 promotes inflammation in rheumatoid arthritis. Front Immunol. 2018;9:2537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6224447</ArticleId><ArticleId IdType="pubmed">30450102</ArticleId></ArticleIdList></Reference><Reference><Citation>Ka SM, Huang XR, Lan HY, Tsai PY, Yang SM, Shui HA, et al. Smad7 gene therapy ameliorates an autoimmune crescentic glomerulonephritis in mice. J Am Soc Nephrol. 2007;18(6):1777&#x2013;1788.</Citation><ArticleIdList><ArticleId IdType="pubmed">17475816</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng J, Montecalvo A, Kane LP. Regulation of NF-&#x3ba;B induction by TCR/CD28. Immunol Res. 2011;50(2&#x2013;3):113&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066383</ArticleId><ArticleId IdType="pubmed">21717079</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden MS, Ghosh S. NF-&#x3ba;B, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012;26(3):203&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3278889</ArticleId><ArticleId IdType="pubmed">22302935</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">21376230</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinatizadeh MR, Schock B, Chalbatani GM, Zarandi PK, Jalali SA, Miri SR. The Nuclear factor Kappa B (NF-kB) signaling in cancer development and immune diseases. Genes &amp; Diseases. 2021;8(3):287&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8093649</ArticleId><ArticleId IdType="pubmed">33997176</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia L, Tan S, Zhou Y, Lin J, Wang H, Oyang L, et al. Role of the NF&#x3ba;B-signaling pathway in cancer. Onco Targets Ther. 2018;11:2063&#x2013;2073.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5905465</ArticleId><ArticleId IdType="pubmed">29695914</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaptulbarova K, Tsyganov M, Pevzner A, Ibragimova M, Litviakov N. NF-kB as a potential prognostic marker and a candidate for targeted therapy of cancer. Exp Oncol. 2020;42:263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">33355866</ArticleId></ArticleIdList></Reference><Reference><Citation>Verzella D, Pescatore A, Capece D, Vecchiotti D, Ursini MV, Franzoso G, et al. Life, death, and autophagy in cancer: NF-&#x3ba;B turns up everywhere. Cell Death Dis. 2020;11(3):210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7105474</ArticleId><ArticleId IdType="pubmed">32231206</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Shao L, Creighton CJ, Zhang Y, Xin L, Ittmann M, et al. Function of phosphorylation of NF-kB p65 ser536 in prostate cancer oncogenesis. Oncotarget. 2015;6(8):6281&#x2013;6294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4467437</ArticleId><ArticleId IdType="pubmed">25749044</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CY, Wang CJ, Tseng CC, Chen HP, Wu MS, Lin JT, et al. Helicobacter pylori promote gastric cancer cells invasion through a NF-kappaB and COX-2-mediated pathway. World J Gastroenterol. 2005;11(21):3197&#x2013;3203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4316048</ArticleId><ArticleId IdType="pubmed">15929167</ArticleId></ArticleIdList></Reference><Reference><Citation>Man X, Piao C, Lin X, Kong C, Cui X, Jiang Y. USP13 functions as a tumor suppressor by blocking the NF-kB-mediated PTEN downregulation in human bladder cancer. J Exp Clin Cancer Res. 2019;38(1):259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6570860</ArticleId><ArticleId IdType="pubmed">31200745</ArticleId></ArticleIdList></Reference><Reference><Citation>Torrealba N, Vera R, Fraile B, Mart&#xed;nez-Onsurbe P, Paniagua R, Royuela M. TGF-&#x3b2;/PI3K/AKT/mTOR/NF-kB pathway. Clinicopathological features in prostate cancer. The Aging Male. 2020;23(5):801&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">30973040</ArticleId></ArticleIdList></Reference><Reference><Citation>Wertz IE, Dixit VM. Signaling to NF-kappaB: regulation by ubiquitination. Cold Spring Harb Perspect Biol. 2010;2(3):a003350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2829959</ArticleId><ArticleId IdType="pubmed">20300215</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelinski Y, Hidaoui D, Stolz A, Hermetet F, Chelbi R, Diop MK, et al. NF-&#x3ba;B signaling controls H3K9me3 levels at intronic LINE-1 and hematopoietic stem cell genes in cis. J Exp Med. 2022 doi: 10.1084/jem.20211356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20211356</ArticleId><ArticleId IdType="pmc">PMC9274146</ArticleId><ArticleId IdType="pubmed">35802137</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, Yan B, Yu H, Ren J, Peng M, Zhu L, et al. OTUD1 stabilizes PTEN to inhibit the PI3K/AKT and TNF-alpha/NF-kappaB signaling pathways and sensitize ccRCC to TKIs. Int J Biol Sci. 2022;18(4):1401&#x2013;1414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8898358</ArticleId><ArticleId IdType="pubmed">35280681</ArticleId></ArticleIdList></Reference><Reference><Citation>Housley WJ, Fernandez SD, Vera K, Murikinati SR, Grutzendler J, Cuerdon N, et al. Genetic variants associated with autoimmunity drive NF&#x3ba;B signaling and responses to inflammatory stimuli. Science Transl Med. 2015;7(291):291ra93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4574294</ArticleId><ArticleId IdType="pubmed">26062845</ArticleId></ArticleIdList></Reference><Reference><Citation>Dissanayake D, Hall H, Berg-Brown N, Elford AR, Hamilton SR, Murakami K, et al. Nuclear factor-&#x3ba;B1 controls the functional maturation of dendritic cells and prevents the activation of autoreactive T cells. Nat Med. 2011;17(12):1663&#x2013;1667.</Citation><ArticleIdList><ArticleId IdType="pubmed">22081022</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavares RM, Turer EE, Liu CL, Advincula R, Scapini P, Rhee L, et al. The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity. Immunity. 2010;33(2):181&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2931361</ArticleId><ArticleId IdType="pubmed">20705491</ArticleId></ArticleIdList></Reference><Reference><Citation>Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast cancer statistics, 2022. CA: a cancer J Clin. 2022 doi: 10.3322/caac.21754.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21754</ArticleId><ArticleId IdType="pubmed">36190501</ArticleId></ArticleIdList></Reference><Reference><Citation>About Breast Cancer. American Cancer Society. 2021.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>